Bright Minds Biosciences Inc. (DRUG) closed the last trading session at $38.89, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $83.25 indicates an 114.1% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $7.68. While the lowest estimate of $75.00 indicates a 92.9% increase from the current price level, the most opt ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, PortugalDATE: August 30 – September ...

Barth syndrome is an ultra-rare genetic condition characterized by exercise intolerance, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. The disease is associated with reduced life expectancy, with 85% of early deaths occurring by age 5. Barth syndrome occurs almost exclusively in males and is estimated to affect one in 1,000,000 males worldwide or around 150 individuals in the United States. There are currently no FDA- or EMA-approved therapies for patients w ...

Core Viewpoint - Chardan Research has initiated coverage on Bright Minds Biosciences Inc., focusing on its lead product BMB-101, an epilepsy drug developed using structure-based drug design [1][2]. Company Overview - Bright Minds Biosciences Inc. is an epilepsy drug developer with a focus on chronic treatment for neurological disorders [1]. - The company's lead product, BMB-101, is a novel scaffold 5-HT2C Gq-protein biased agonist [1]. Product Details - BMB-101 is designed to address tolerance and drug resistance issues common in chronic neurological treatments [1]. - The drug has shown efficacy in preclinical studies for conditions such as Dravet Syndrome and generalized seizures [2]. - The ongoing BREAKTHROUGH Phase 2 study is evaluating BMB-101's safety, tolerability, and efficacy in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE) [2]. Market Potential - Analyst Rudy Li projects over $1 billion in combined peak sales for DEE and absence epilepsy, indicating significant market potential [3]. - The stock has gained attention following the acquisition of Longboard Pharmaceuticals by H. Lundbeck A/S, which highlights the competitive landscape for 5-HT2C agonists [4]. Investment Perspective - Chardan views Bright Minds Biosciences as a high-risk, high-reward investment opportunity, despite the partially validated mechanism of action [5]. - The stock price has increased by 4.84%, reaching $30.43, reflecting positive market sentiment [5].

Group 1 - The company Bright Minds Biosciences (NASDAQ: DRUG) is considered undervalued and has been initiated with a Buy rating [1] - A near-term catalyst for its primary asset, BMB-101, is expected in Q2 2025, which could drive value [1] - The company has a decent balance sheet and a significant market opportunity, indicating potential for growth [1]

Core Insights - Bright Minds Biosciences Inc. is expanding its Scientific Advisory Board (SAB) to enhance its clinical focus on epilepsy, particularly in the development of 5-HT2 agonists for drug-resistant epilepsy and related CNS disorders [1][2] - The company is currently conducting a Phase 2 BREAKTHROUGH study of BMB-101 targeting adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE) [1][2] - The addition of five distinguished experts in epilepsy research to the SAB is expected to provide invaluable guidance for the company's clinical programs and regulatory processes [1][2] Company Overview - Bright Minds is a biotechnology company dedicated to developing innovative treatments for neurological and psychiatric disorders, with a focus on high unmet medical needs such as epilepsy and depression [12][13] - The company has developed a unique platform of highly selective serotonergic agonists, which has resulted in a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [13] Scientific Advisory Board Members - The newly added SAB members include: - Dennis Dlugos, MD, an expert in pediatric epilepsy and clinical trials [3] - Jacqueline French, MD, a leader in early phase epilepsy trials and the Medical Director of the Epilepsy Foundation [4] - Terence O'Brien, MD, a specialist in neurology and clinical pharmacology with extensive research experience [5] - Jo Sourbron, MD, PhD, MPharm, focused on genetic forms of epilepsy and clinical trials for drug-resistant epilepsy [8] - Joseph Sullivan, MD, a pediatric epilepsy expert with a focus on Dravet syndrome [9] - These experts join existing SAB members, enhancing the company's advisory capabilities in epilepsy research [10] Clinical Development Focus - The company is committed to pursuing therapies that reduce seizure frequency and improve the quality of life for patients with drug-resistant epilepsy, which affects over 70 million people globally [2]

Financial Performance - The company achieved a net income of CAD 49,610 for the three months ended December 31, 2024, compared to a net loss of CAD 1,684,267 for the same period in 2023[5] - Basic earnings per share improved to CAD 0.01 for the quarter ended December 31, 2024, compared to a loss of CAD 0.44 per share in the same quarter of 2023[5] - The company reported a working capital of CAD 57,760,114 as of December 31, 2024, compared to CAD 5,458,261 on September 30, 2024, reflecting improved financial health[12] - The total shareholders' equity increased to CAD 57,827,039 as of December 31, 2024, compared to CAD 5,536,343 as of September 30, 2024[2] Assets and Liquidity - As of December 31, 2024, Bright Minds Biosciences Inc. reported total assets of CAD 58,398,629, a significant increase from CAD 6,104,602 as of September 30, 2024[2] - Cash and cash equivalents rose to CAD 57,896,665 as of December 31, 2024, up from CAD 5,720,092 at the end of September 2024, indicating strong liquidity[9] - The company has a liquidity position with cash and cash equivalents covering current liabilities of $461,522, indicating a strong liquidity buffer[71] Expenses and Cost Management - Research and development expenses for the quarter were CAD 1,045,368, down from CAD 1,225,524 in the same quarter of 2023[5] - Total share-based compensation expense for the three months ended December 31, 2024, was $176,391, a decrease of 19.4% from $218,949 in the same period of 2023[48] - The company incurred laboratory costs of $2,680 and novel drug development expenses of $277,342 for the three months ended December 31, 2024[73] Capital Raising and Financing - The company raised CAD 48,628,964 through private placements during the quarter, significantly boosting its capital[9] - The company plans to finance future operations through equity financings and loans from directors, indicating a strategy for sustainable growth[12] - The company closed a non-brokered private placement on November 4, 2024, issuing 1,612,902 common shares for gross proceeds of $48,628,964 (US$35,000,000) with share issuance costs of $83,720[31] Stock Options and Equity Activity - The balance of outstanding stock options as of December 31, 2024, was 299,350 with a weighted average exercise price of $6.11 and a remaining life of 3.44 years[42] - The company granted 70,000 stock options on October 3, 2024, with an exercise price of $1.65 per share, which expire on October 3, 2029[40] - The company recognized stock options expense of $129,251 and restricted share units expense of $47,140 for the three months ended December 31, 2024[48] - On January 27, 2025, the company issued 55,000 common shares upon the exercise of RSUs, indicating ongoing equity activity[78] Liabilities and Obligations - As of December 31, 2024, total accounts payable and accrued liabilities decreased to $388,857 from $449,299 as of September 30, 2024, representing a reduction of approximately 13.4%[29] - The company reported a decrease in accounts payable to related parties, from $61,061 as of September 30, 2024, to $32,836 as of December 31, 2024[53] - The company has a contractual obligation to pay royalties on net sales ranging from 3% to 4.5%, depending on sales volume, with annual minimum payments starting at $5,000 in Year 3[56] Risk Factors - The company is exposed to foreign exchange risk, with a potential impact of approximately $5,132,000 on comprehensive income from a 10% fluctuation in the US dollar and Australian dollar against the Canadian dollar[70] - The company has a concentration of credit risk with cash and cash equivalents held with three major banks, assessed as low credit risk[69] Management and Advisory - The total expenses related to key management personnel for the three months ended December 31, 2024, amounted to $627,947, significantly higher than $321,439 in the same period of 2023[54] - The company granted 12,000 RSUs to advisors as part of its scientific advisory board agreements[63] - The company has entered into consulting agreements with hourly rates ranging from $30 to $600, with a total of 60,400 stock options granted to advisors[64] Accounting and Compliance - The company has not yet determined the impact of amendments to accounting standards on its financial statements, which are effective from January 1, 2024[28]

Regulatory and Compliance - DMG Blockchain Solutions Inc. was issued a failure-to-file cease trade order on February 1, 2019, which was revoked on August 28, 2019[42]. - The Company has adopted a policy prohibiting directors, officers, and employees from hedging or monetizing transactions to lock in the value of holdings in securities[79]. Executive Compensation - The Compensation Committee reviews executive compensation annually, considering factors such as performance, industry standards, and available cash resources[51]. - The Company does not offer any benefits or perquisites to its Named Executive Officers other than potential grants of incentive stock options and RSUs[78]. - The compensation program aims to attract and retain qualified executives while aligning their interests with those of the Company's shareholders[54]. - The Company has not retained a compensation consultant during the financial years ending September 30, 2024, 2023, or 2022[77]. - The Board has concluded that the compensation policies do not create risks likely to have a material adverse effect on the Company[52]. - The Company does not have a pension plan providing payments or benefits to Named Executive Officers upon retirement[81]. - The Summary Compensation Table outlines all compensation provided to executive officers for their services[82]. - Total compensation for Ian McDonald, President and CEO, in 2024 was C$213,239, a decrease from C$626,178 in 2023[83]. - Ryan Cheung, CFO, received a total compensation of C$120,000 for both 2024 and 2023, unchanged from 2023[83]. - Jan Pedersen, Chief Science Officer, earned C$448,583 in 2024, down from C$799,724 in 2023[83]. - Mark Smith, Chief Medical Officer, received C$407,924 in 2024, compared to C$450,921 in 2023[83]. Equity Compensation - The equity compensation plans include 340,400 options and 192,000 RSUs, with a weighted-average exercise price of $7.76[90]. - There are 112,008 options and 260,408 RSUs remaining available for future issuance under the equity compensation plans[90]. - The company adopted a 10% rolling stock option plan, effective July 1, 2020, which allows for the issuance of options up to 10% of the total issued and outstanding common shares[113]. - The maximum number of options granted to any one holder within a 12-month period is limited to 5% of the issued and outstanding common shares[119]. Financial Position - The company has a total of 4,524,087 common shares outstanding as of the end of the reporting period[98]. - As of September 30, 2024, the company had cash and cash equivalents of C$5,720,092, which is held with major banks in Canada, the United States, and Australia[368]. - The company completed a private placement raising C$35,000,000, distributing 1,612,902 common shares at a price of C$21.70 per share[371]. - The company has current liabilities of C$449,299, indicating a strong liquidity position with cash reserves significantly exceeding liabilities[371]. - The company has no off-balance sheet arrangements or transactions that may materially affect its financial conditions[122]. Operational Risks - The company has limited experience in completing clinical trials, having only completed one phase one drug trial to date[137]. - The company operates solely through consultants and independent contractors, with its subsidiary having one employee as of December 30, 2024[157]. - The company faces risks related to foreign exchange fluctuations, particularly with US and Australian dollar balances[370]. - The company has a concentration of credit risk due to cash deposits being held with three banks[368]. - The company may not achieve the timelines for project development set out in its annual report, indicating potential delays in product development[139]. - The company’s management of capital did not change during the year ended September 30, 2024, focusing on maintaining adequate capital resources[372].

Core Insights - Cumberland Pharmaceuticals Inc. has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for Ifetroban, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] - The company is conducting the FIGHT DMD™ trial, a Phase II study to evaluate the pharmacokinetics, safety, and efficacy of Ifetroban in DMD patients, with results expected later this year [1][2] Regulatory Designations - The Rare Pediatric Disease Designation is intended to incentivize drug development for life-threatening diseases affecting fewer than 200,000 children in the U.S., providing potential benefits such as a priority review voucher for other products [2] - Orphan Drug Designation offers multiple incentives, including exemption from user fees, tax credits for clinical trials, and potential market exclusivity for seven years post-approval [3] Disease Overview - Duchenne muscular dystrophy is a rare genetic disorder affecting approximately 1 in every 3,300 male births globally, leading to severe damage to skeletal and cardiac muscles, with cardiomyopathy being a primary cause of mortality [4] - Ifetroban is being evaluated specifically for its effects on heart disease associated with DMD, an area that has seen limited therapeutic focus [4] Drug Profile - Ifetroban is characterized as a potent and selective thromboxane-prostanoid receptor antagonist, showing promise in preclinical models by preventing cardiac fibrosis and dysfunction, and improving mortality rates [5] Additional Research - Cumberland is also exploring Ifetroban for other conditions, including systemic sclerosis and pulmonary fibrosis, with ongoing trials assessing its safety and efficacy in idiopathic pulmonary fibrosis [7] Company Background - Cumberland Pharmaceuticals focuses on delivering high-quality prescription brands for hospital acute care, gastroenterology, and rheumatology, with a portfolio that includes several FDA-approved products [8][9]

Core Viewpoint - Bright Minds Biosciences Inc. has successfully closed a non-brokered private placement, raising a total of USD$35 million through the issuance of 1,612,902 common shares at a price of USD$21.70 per share [1][2]. Group 1: Offering Details - The private placement attracted participation from notable investors including Cormorant Asset Management, RA Capital Management, and Janus Henderson Investors, among others [2]. - Insiders, including a director of the Company, subscribed for 188,940 shares, contributing approximately USD$4.1 million to the total proceeds [3]. - All securities issued are subject to a statutory hold period of four months and one day, and no finder's fees were paid in connection with the Offering [4]. Group 2: Use of Proceeds - The Company plans to utilize the gross proceeds from the Offering for research and development related to its drug development programs and for general working capital [2]. Group 3: Company Overview - Bright Minds Biosciences is focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key receptors in the brain [7]. - The Company aims to deliver breakthrough therapies for conditions with high unmet medical needs, such as epilepsy and depression [7].